Cargando…
Safety and Tolerability of Fingolimod in Latin American Patients with Relapsing-Remitting Multiple Sclerosis: The Open-Label FIRST LATAM Study
INTRODUCTION: Fingolimod 0.5 mg is an orally active sphingosine 1-phosphate receptor modulator approved for use in adults with relapsing multiple sclerosis (MS). The efficacy and safety profile of fingolimod has been well characterized in a large clinical development program. Here, we report the saf...
Autores principales: | Ordoñez-Boschetti, Laura, Rey, Roberto, Cruz, Ana, Sinha, Arijit, Reynolds, Tracy, Frider, Nadina, Alvarenga, Regina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4522027/ https://www.ncbi.nlm.nih.gov/pubmed/26170105 http://dx.doi.org/10.1007/s12325-015-0224-2 |
Ejemplares similares
-
Erratum to: Safety and Tolerability of Fingolimod in Latin American Patients with Relapsing-Remitting Multiple Sclerosis: The Open-Label FIRST LATAM Study
por: Ordoñez-Boschetti, Laura, et al.
Publicado: (2015) -
Use of Fingolimod in the Management of Relapsing–Remitting Multiple Sclerosis: Experience from Latin America
por: Correale, Jorge, et al.
Publicado: (2015) -
Assessing the potential impact of non-proprietary drug copies on quality of medicine and treatment in patients with relapsing multiple sclerosis: the experience with fingolimod
por: Correale, Jorge, et al.
Publicado: (2014) -
Safety and efficacy of fingolimod in Iranian patients with relapsing-remitting multiple sclerosis: An open-label study
por: Doosti, Rozita, et al.
Publicado: (2021) -
Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis
por: Kuhle, Jens, et al.
Publicado: (2015)